Ignaty Leshchiner, PhD
Associate Professor (appointment pending)
Boston University Chobanian & Avedisian School of Medicine
Medicine
Computational Biomedicine




Dr. Leshchiner is interested in applying new genomic technologies such as blood biopsy, long-range read phasing, and single cell sequencing for analysis and understanding of biology behind tumor development, treatment evasion, and progression to metastasis. His background is in developing statistical methods for analysis of genomics data and application of these methods to understanding biology and finding treatment for various disease conditions.

Prior to joining Boston University, Dr. Leshchiner served as the associate director of the Computation Biology and Cancer Resistance Department of the Broad Institute of MIT and Harvard. He remains a member of the institute's affiliated faculty. Leshchiner also worked for Partners Healthcare as a bioinformatician in the genetics division of Brigham and Women’s Hospital, where he contributed to the CLARITY Challenge-winning team in 2012. He has previous consulting experience for Hybrid Silica Technologies and prior research fellowships at UMass Lowell and Moscow State University.

Dr. Leshchiner obtained a Ph.D. in chemistry from Moscow State University, which included a visiting scientist appointment in the Langer Lab at MIT. He completed postdoctoral training in bioinformatics and computational biology at Harvard Medical School.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD, Spellman PT, Wedge DC, Van Loo P. Author Correction: The evolutionary history of 2,658 cancers. Nature. 2023 Feb; 614(7948):E42. PMID: 36697833; PMCID: PMC9931577; DOI: 10.1038/s41586-022-05601-4;
     
  2. Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 Jan; 29(1):158-169. PMID: 36624313
     
  3. Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Getz G, Jeselsohn R. Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2022 Dec 01; 28(23):5066-5078. PMID: 36215125; PMCID: PMC9722539; DOI: 10.1158/1078-0432.CCR-22-2305;
     
  4. Drummond BE, Chambers BE, Wesselman HM, Gibson S, Arceri L, Ulrich MN, Gerlach GF, Kroeger PT, Leshchiner I, Goessling W, Wingert RA. osr1 Maintains Renal Progenitors and Regulates Podocyte Development by Promoting wnt2ba via the Antagonism of hand2. Biomedicines. 2022 Nov 09; 10(11). PMID: 36359386; PMCID: PMC9687957; DOI: 10.3390/biomedicines10112868;
     
  5. Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale SP, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR. Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance. Blood Adv. 2022 Oct 26. PMID: 36287227
     
  6. Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med. 2022 02 15; 3(2):100500. PMID: 35243413; PMCID: PMC8861826; DOI: 10.1016/j.xcrm.2021.100500;
     
  7. Penter L, Gohil SH, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ. Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 Dec 01; 11(12):3048-3063. PMID: 34112698; PMCID: PMC8660953; DOI: 10.1158/2159-8290.CD-21-0276;
     
  8. Koltowska K, Okuda KS, Gloger M, Rondon-Galeano M, Mason E, Xuan J, Dudczig S, Chen H, Arnold H, Skoczylas R, Bower NI, Paterson S, Lagendijk AK, Baillie GJ, Leshchiner I, Simons C, Smith KA, Goessling W, Heath JK, Pearson RB, Sanij E, Schulte-Merker S, Hogan BM. The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 function. Nat Cell Biol. 2021 11; 23(11):1136-1147. PMID: 34750583; DOI: 10.1038/s41556-021-00784-w;
     
  9. Tewari AK, Cheung ATM, Crowdis J, Conway JR, Camp SY, Wankowicz SA, Livitz DG, Park J, Lis RT, Bosma-Moody A, He MX, AlDubayan SH, Zhang Z, McKay RR, Leshchiner I, Brown M, Balk SP, Getz G, Taplin ME, Van Allen EM. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep. 2021 09 07; 36(10):109665. PMID: 34496240; DOI: 10.1016/j.celrep.2021.109665;
     
  10. Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A, Ellisen LW. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021 10; 11(10):2436-2445. PMID: 34404686; PMCID: PMC8495771; DOI: 10.1158/2159-8290.CD-21-0702;
     
Showing 10 of 52 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 52 publications over 14 distinct years, with a maximum of 8 publications in 2018

YearPublications
20081
20101
20122
20131
20142
20155
20163
20176
20188
20197
20204
20216
20224
20232

Contact for Mentoring:

72 E. Concord Street
Boston MA 02118
Google Map


Leshchiner's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department